Comparative Pharmacology
Head-to-head clinical analysis: CEFTAZIDIME versus MANDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAZIDIME versus MANDOL.
CEFTAZIDIME vs MANDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against Gram-negative bacteria, including Pseudomonas aeruginosa.
Cephalosporin antibiotic; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
1-2 g IV every 8 hours
1-2 g IV or IM every 4-8 hours; maximum 12 g/day.
None Documented
None Documented
2 hours (range 1.2-2.2 h) in normal renal function; prolonged to 10-15 h in end-stage renal disease; requires dose adjustment.
Clinical Note
moderateCeftazidime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ceftazidime."
Clinical Note
moderateCefamandole + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefamandole."
Clinical Note
moderateCeftazidime + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftazidime."
Clinical Note
moderateCefamandole + Picosulfuric acid
Terminal elimination half-life is 1.2-1.8 hours in adults with normal renal function; prolonged to 4-8 hours in moderate renal impairment (CrCl 30-50 mL/min) and >12 hours in severe impairment (CrCl <30 mL/min).
Primarily renal: 80-90% excreted unchanged in urine via glomerular filtration; small amount (≈1%) biliary; ≤1% fecal.
Renal: 65-85% unchanged via glomerular filtration and tubular secretion; biliary/fecal: ~15-20% as active drug and metabolites; minor hepatic metabolism.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefamandole."